Subfoveal fibrosis associated with AMD linked to classic CNV, significant vision loss
Subfoveal fibrosis in age-related macular degeneration was associated with the development of classic choroidal neovascularization, poorer visual acuity, longer duration of disease and greater visual loss, according to a study.
The retrospective study included 197 eyes of 197 patients with choroidal neovascularization related to AMD without subfoveal fibrosis at presentation. Patients were treated with Lucentis (ranibizumab, Genentech).
Optical coherence tomography and color fundus photography were used to evaluate subfoveal fibrosis and retinal atrophy from 16 weeks after the first ranibizumab injection.
Mean follow-up was 1.8 years. The main outcome measure was presence of subfoveal fibrosis at final follow-up.
Eyes with prominent fibrosis lost 8.5 more letters of vision, and those with fibrosis and foveal atrophy lost 10.3 more letters than eyes without fibrosis at 2 years (P = .0242 and P = .0012, respectively).
Best corrected visual acuity was 12.2 letters lower in eyes with type 2 lesions than in those with type 1 lesions; the difference was statistically significant (P = .0003). However, eyes with type 2 lesions did not lose significantly more letters than those with type 1 lesions, according to the authors.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.